Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
3 No-Brainer Stocks to Buy With $1,000 During the Market Sell-Off
09:51am, Friday, 01'st Apr 2022 The Motley Fool
A tumbling market is the perfect opportunity to buy into these highly profitable and attractively priced stocks.
2 Stocks Defying the Market Sell-Off Right Now
03:15pm, Tuesday, 29'th Mar 2022 The Motley Fool
Are these two companies solid long-term bets?
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
02:00pm, Monday, 21'st Mar 2022 Zacks Investment Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
11:17am, Monday, 21'st Mar 2022
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Biotech Stock Roundup: NKTR Plunges on Study Failure, MRNA Offers Updates & More
04:32pm, Wednesday, 16'th Mar 2022 Zacks Investment Research
Pipeline and regulatory updates from Nektar (NKTR) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.
Exelixis (EXEL) Announces Final Results From HCC Study
04:03pm, Tuesday, 15'th Mar 2022 Zacks Investment Research
Exelixis (EXEL) does not intend to submit a supplemental new drug application to the FDA for Cabometyx in patients with previously untreated advanced hepatocellular carcinoma.
Exelixis (EXEL) Announces Final Results From HCC Study
01:33pm, Tuesday, 15'th Mar 2022
Exelixis (EXEL) does not intend to submit a supplemental new drug application to the FDA for Cabometyx in patients with previously untreated advanced hepatocellular carcinoma.
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
11:46am, Tuesday, 15'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Anaptys Discontinues Phase 2 Study Of Imsidolimab In Acne
Anaptys Bio, Inc. (NASDAQ: ANAB) said the Ph
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
10:53am, Tuesday, 15'th Mar 2022 Benzinga
Exelixis Inc (NASDAQ: EXEL ) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus atezolizumab versus sorafenib in untreated hepatocellular carcinoma (HCC). The final analysis showed neither improvement nor detriment in OS for cabozantinib/atezolizumab … Full story available on Benzinga.com
Exelixis: Hepatocellular Carcinoma Trial Findings Showed No Improvement
08:45pm, Monday, 14'th Mar 2022 MarketWatch
By Denny Jacob Exelixis Inc. shares declined 3.1% to $19.95 in Monday''s after-hours trading after the biopharmaceutical company said its Phase 3 trial of a…
Exelixis opts not to seek label expansion for Cabometyx
08:34pm, Monday, 14'th Mar 2022 Seeking Alpha
Exelixis (EXEL) announced on Monday that the company would no longer pursue its planned submission of the supplemental New Drug Application for its cancer therapy, Cabometyx, to the U.S
3 Stocks That Can Turn $10,000 Into $50,000 by 2025
11:30am, Friday, 11'th Mar 2022 The Motley Fool
Revenue is ready to soar at these companies.
3 Stocks That Can Turn $10,000 Into $50,000 by 2025
06:30am, Friday, 11'th Mar 2022
Revenue is ready to soar at these companies.
2 Biotech Stocks That Could Make You Richer
12:02pm, Wednesday, 02'nd Mar 2022 The Motley Fool
These two biotech stocks already have blockbuster therapies that are driving increased revenue.
2 Biotech Stocks That Could Make You Richer
07:02am, Wednesday, 02'nd Mar 2022
These two biotech stocks already have blockbuster therapies that are driving increased revenue.
